|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shuch B, Amin A, Armstrong AJ, Eble JN,
Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI and Kutikov A:
Understanding pathologic variants of renal cell carcinoma:
Distilling therapeutic opportunities from biologic complexity. Eur
Urol. 67:85–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Capitanio U and Montorsi F: Renal cancer:
Lancet. 387:894–906. 2016.
|
|
4
|
Endele S, Fuhry M, Pak SJ, Zabel BU and
Winterpacht A: LETM1, a novel gene encoding a putative EF-hand
Ca(2+)-binding protein, flanks the Wolf-Hirschhorn syndrome (WHS)
critical region and is deleted in most WHS patients. Genomics.
60:218–225. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nowikovsky K, Froschauer EM, Zsurka G,
Samaj J, Reipert S, Kolisek M, Wiesenberger G and Schweyen RJ: The
LETM1/YOL027 gene family encodes a factor of the mitochondrial K+
homeostasis with a potential role in the Wolf-Hirschhorn syndrome.
J Biol Chem. 279:30307–30315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Piao L, Li Y, Kim SJ, Byun HS, Huang SM,
Hwang SK, Yang KJ, Park KA, Won M, Hong J, et al: Association of
LETM1 and MRPL36 contributes to the regulation of mitochondrial ATP
production and necrotic cell death. Cancer Res. 69:3397–3404. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen L, Yang Y, Liu S, Piao L, Zhang Y,
Lin Z and Li Z: High expression of leucine zipper-EF-hand
containing transmembrane protein 1 predicts poor prognosis in head
and neck squamous cell carcinoma. Biomed Res Int.
2014:8503162014.PubMed/NCBI
|
|
8
|
Huang B, Zhang J, Zhang X, Huang C, Hu G,
Li S, Xie T, Liu M and Xu Y: Suppression of LETM1 by siRNA inhibits
cell proliferation and invasion of bladder cancer cells. Oncol Rep.
38:2935–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li N, Zheng Y, Xuan C, Lin Z, Piao L and
Liu S: LETM1 overexpression is correlated with the clinical
features and survival outcome of breast cancer. Int J Clin Exp
Pathol. 8:12893–12900. 2015.PubMed/NCBI
|
|
10
|
Wang CA, Liu Q, Chen Y, Liu S, Xu J, Cui
X, Zhang Y and Piao L: Clinical implication of leucine zipper/EF
hand-containing transmembrane-1 overexpression in the prognosis of
triple-negative breast cancer. Exp Mol Pathol. 98:254–259. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koul H, Huh JS, Rove KO, Crompton L, Koul
S, Meacham RB and Kim FJ: Molecular aspects of renal cell
carcinoma: A review. Am J Cancer Res. 1:240–254. 2011.PubMed/NCBI
|
|
13
|
Rini BI: Vascular endothelial growth
factor-targeted therapy in metastatic renal cell carcinoma. Cancer.
115 10 Suppl:S2306–S2312. 2009. View Article : Google Scholar
|
|
14
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Figlin RA: Renal cell carcinoma:
Management of advanced disease. J Urol. 161:381–367. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lanigan D: Prognostic factors in renal
cell carcinoma. Br J Urol. 75:565–571. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hwang SK, Piao L, Lim HT, Minai-Tehrani A,
Yu KN, Ha YC, Chae CH, Lee KH, Beck GR, Park J and Cho MH:
Suppression of lung tumorigenesis by leucine zipper/EF
hand-containing transmembrane-1. PLoS One. 5:pii: e125352010.
View Article : Google Scholar
|
|
18
|
Doonan PJ, Chandramoorthy HC, Hoffman NE,
Zhang X, Cárdenas C, Shanmughapriya S, Rajan S, Vallem S, Chen X,
Foskett JK, et al: LETM1-dependent mitochondrial Ca2+ flux
modulates cellular bioenergetics and proliferation. FASEB J.
28:4936–4949. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cojocaru E, Lozneanu L, Giuşcă SE, Căruntu
ID and Danciu M: Renal carcinogenesis-insights into signaling
pathways. Rom J Morphol Embryol. 56:15–19. 2015.PubMed/NCBI
|
|
20
|
Wang X, Lu X, Geng Z, Yang G and Shi Y:
LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration
of papillary thyroid carcinoma via Wnt/β-catenin signaling. J Cell
Biochem. 118:4745–4752. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan H, Yu S, Cui Y, Men C, Yang D, Gao Z,
Zhu Z and Wu J: Knockdown of mediator subunit Med19 suppresses
bladder cancer cell proliferation and migration by downregulating
Wnt/β-catenin signalling pathway. J Cell Mol Med. 21:3254–3263.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rahmani F, Avan A, Hashemy SI and
Hassanian SM: Role of Wnt/β-catenin signaling regulatory microRNAs
in the pathogenesis of colorectal cancer. J Cell Physiol.
233:811–817. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Polakis P: The many ways of Wnt in cancer.
Curr Opin Genet Dev. 17:45–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
